BR112015023332A2 - Toxóide, composições e método relacionados - Google Patents

Toxóide, composições e método relacionados

Info

Publication number
BR112015023332A2
BR112015023332A2 BR112015023332A BR112015023332A BR112015023332A2 BR 112015023332 A2 BR112015023332 A2 BR 112015023332A2 BR 112015023332 A BR112015023332 A BR 112015023332A BR 112015023332 A BR112015023332 A BR 112015023332A BR 112015023332 A2 BR112015023332 A2 BR 112015023332A2
Authority
BR
Brazil
Prior art keywords
methods
toxoid
compositions
inactivating
toxoids
Prior art date
Application number
BR112015023332A
Other languages
English (en)
Portuguese (pt)
Inventor
HAUSER Steven
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of BR112015023332A2 publication Critical patent/BR112015023332A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BR112015023332A 2013-03-15 2014-03-14 Toxóide, composições e método relacionados BR112015023332A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790423P 2013-03-15 2013-03-15
PCT/US2014/029035 WO2014144567A2 (en) 2013-03-15 2014-03-14 Toxoid, compositions and related methods

Publications (1)

Publication Number Publication Date
BR112015023332A2 true BR112015023332A2 (pt) 2017-08-22

Family

ID=50489430

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023332A BR112015023332A2 (pt) 2013-03-15 2014-03-14 Toxóide, composições e método relacionados

Country Status (13)

Country Link
US (2) US20160045586A1 (cg-RX-API-DMAC7.html)
EP (1) EP2968507A2 (cg-RX-API-DMAC7.html)
JP (1) JP2016516721A (cg-RX-API-DMAC7.html)
KR (1) KR20150133770A (cg-RX-API-DMAC7.html)
CN (1) CN105338997A (cg-RX-API-DMAC7.html)
AR (1) AR095669A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014228956A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015023332A2 (cg-RX-API-DMAC7.html)
CA (1) CA2907154A1 (cg-RX-API-DMAC7.html)
HK (1) HK1213800A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201507608PA (cg-RX-API-DMAC7.html)
TW (1) TWI624474B (cg-RX-API-DMAC7.html)
WO (1) WO2014144567A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
BR112017024443A2 (pt) * 2015-05-15 2018-10-23 Sanofi Pasteur Inc métodos para imunização contra clostridium difficile
MX388528B (es) 2017-06-09 2025-03-20 Hipra Scient S L U Vacuna que comprende toxoides de clostridium.
US10096313B1 (en) * 2017-09-20 2018-10-09 Bose Corporation Parallel active noise reduction (ANR) and hear-through signal flow paths in acoustic devices
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
EP4444742A4 (en) * 2021-12-06 2025-12-10 Univ Rutgers Compositions and Methods for Treating Cancer
EP4658302A1 (en) 2023-02-02 2025-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US5610023A (en) * 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP2305303A3 (en) * 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6669520B2 (en) 2001-09-19 2003-12-30 United Microelectronics Corp. Method of fabricating an LC panel
JP2010534622A (ja) 2007-07-26 2010-11-11 サノフィ パストゥール リミテッド 抗原−アジュバント組成物および方法
AU2008299885C1 (en) * 2007-09-14 2015-06-25 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing clostridium difficile toxoids A and B
GB201011968D0 (en) * 2010-07-16 2010-09-01 Secr Defence Toxoiding method

Also Published As

Publication number Publication date
KR20150133770A (ko) 2015-11-30
EP2968507A2 (en) 2016-01-20
CA2907154A1 (en) 2014-09-18
JP2016516721A (ja) 2016-06-09
SG11201507608PA (en) 2015-10-29
WO2014144567A2 (en) 2014-09-18
TW201514197A (zh) 2015-04-16
WO2014144567A3 (en) 2014-12-04
US20160045586A1 (en) 2016-02-18
HK1213800A1 (zh) 2016-07-15
CN105338997A (zh) 2016-02-17
TWI624474B (zh) 2018-05-21
AR095669A1 (es) 2015-11-04
US20180028637A1 (en) 2018-02-01
AU2014228956A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
WO2014144567A3 (en) Toxoid, compositions and related methods
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
CR20200082A (es) Virus chikungunya inmunogénico
SG10201808151RA (en) Cortistatin analogues and syntheses and uses thereof
BR112016012870A2 (pt) ?métodos e composições para melhorar a produção de alface
PH12013502442A1 (en) Inactivated dengue virus vaccine
MX2017004617A (es) Variantes estabilizadas de alfa amilasa y su uso.
PH12018502120A1 (en) Live attenuated alphavirus constructs and methods and uses thereof
MX2015010305A (es) Vacuna de combinacion para virus sincitial respiratorio e influenza.
BR112017000022A2 (pt) nanoparticulas terapêuticas direcionadas a alvo e métodos de produção e uso dessas partículas
NZ710740A (en) Glycopyrrolate salts
MX2015010106A (es) Moduladores de la proteina activadora de 5-lipoxigenasa.
PH12015501888A1 (en) Novel bacteriophage and antibacterial composition comprising the same
PH12014502763A1 (en) Method for the degradation of keratin and use of the keratin hydrolysate produced
BR112015031913A2 (pt) processo para a fabricação de amino-benzoxazinonas 4-propargilatadas e sua utilização
NZ738538A (en) 6-amino-quinoline-3-carbonitrils as cot modulators
BR112017008176A2 (pt) método de preparação do carbonato de ácido glicérico.
BR112013025424A2 (pt) processos para produzir uma composição imunogênica, e para fabricar uma vacina, e, composição imunogênica
UA116697C2 (uk) Композиція для запобігання зараженню видами роду mycoplasma
BR112014029264A2 (pt) microcápsulas contendo um oxidável ativa, e um processo para a preparação do mesmo
BR112016001730A2 (pt) Processo para a preparação de um componente neurotóxico altamente puro de uma toxina botulínica, componente neurotóxico altamente puro de uma toxina de clostridium botulinum e composição farmacêutica
BR102014009838B8 (pt) Método para produzir um l-aminoácido
BR112015027824A2 (pt) composições de vitamina e em pó
BR112017023969A2 (pt) ?microrganismo do gênero escherichia que produz l-triptofano e um método para produzir l- triptofano com o uso do mesmo?
PH12015501335A1 (en) Immunogenic composition comprising mycoplasma antigens

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2557 DE 07/01/2020.